Posts Tagged ‘donanemab’
Systematic review finds more clinical harm than benefits in Alzheimer’s “treatments” lecanemab, aducanumab, and donanemab
Study questions benefit of new Alzheimer’s drug (UGA Today): Last summer, the U.S. Food and Drug Administration fully approved the first drug shown to slow the progress of Alzheimer’s. But new research from the University of Georgia suggests that patients and caregivers may not experience any benefit from the drug in their daily lives. The drug, Leqembi,…
Read MoreBrain imaging AI start-up Neurophet raises $15M to better direct Alzheimer’s treatments, lower ARIA side-effects
Korean AI startups Allganize, Neurophet raise over $35 mn (The Korea Economic Daily): Founded in 2016, the company plans to next year roll out its new AI analysis program that can detect side effects of Alzheimer’s disease treatments with a microhemorrhage diagnosis.
Read MoreFour reasons to question “new generation” monoclonal antibody Alzheimer’s drugs such as aducanumab (Aduhelm), lecanemab (Leqembi), donanemab
New Alzheimer’s Drugs Don’t Deserve the Hype (Being Patient): A prominent childhood memory is of my grandparents living with and then dying from dementia. As is universal with dementia, there was a double blow: watching my grandparents lose their identity and seeing the suffering of those closest to them.
Read More